Skip to main content

Advertisement

Insights into new anticoagulants

 Prof Meyer Michel Samama, Prof Hugo ten Cate

In this Thrombosis Journal series, the greater simplicity and potential of a new class of direct-action oral anticoagulants (DOACs) is explored along with the new challenges they present.

This thematic series has not been sponsored. Articles have been invited by the journal, and have undergone the standard peer review process overseen by the Guest Editors.

MMS declares no conflict of interest. HTC, Chairman of the Dutch Foundation of Anticoagulation Services, has received fees for lectures and consultation from several industries involved in diagnostic anticoagulation tests, or the development of direct-action oral anticoagulants.

  1. Review

    Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays

    Traditional anticoagulant agents such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and fondaparinux have been widely used in the prevention and treatment...

    Jonathan Douxfils, Anne Tamigniau, Bernard Chatelain, Catherine Goffinet, Jean-Michel Dogné and François Mullier

    Thrombosis Journal 2014 12:24

    Published on: 4 November 2014

  2. Review

    Laboratory assessment of rivaroxaban: a review

    Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of whic...

    Meyer Michel Samama, Geneviève Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem, Céline Guinet, Yves Gourmelin, Gabriele Rohde and Jean-Luc Martinoli

    Thrombosis Journal 2013 11:11

    Published on: 3 July 2013

Advertisement